Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrenomedullin for CADASIL
jRCT2051210117Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fispemifene in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Cerebral blood flow change rate in frontal lobe at day 28. Started Jan 2022; status: active, not recruiting.
02
Drugs
fispemifene
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on jRCT2051210117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210117.